Literature DB >> 20608345

What is cancer anorexia-cachexia syndrome? A historical perspective.

N Bennani-Baiti1, D Walsh.   

Abstract

Cancer anorexia-cachexia syndrome (CACS) is a lethal but poorly defined involuntary wasting disorder. Loss of skeletal muscle and fat distinguishes it from starvation. Cachexia has been described as a clinical syndrome since ancient times, and the poor prognosis has long been acknowledged. In this article we have reviewed historical perspectives on cancer cachexia, and commented on modern definitions. In cancer cachexia, most historical descriptions included anorexia, wasting and a pale complexion. Other associated symptoms, such as fatigue, early satiety and taste changes, were inconsistently described. Newer descriptions have not significantly expanded the clinical picture.Today, there is still no consensus definition, hindering research on early diagnosis and effective therapy. The language descriptors used to characterise the syndrome are important. For example, the word 'cachexia' itself may mislead; perhaps cancer-related wasting syndrome is more accurate. Cancer anorexia-cachexia syndrome is a disorder associated with high morbidity and mortality, and deserves greater attention in both clinical and translational research.

Entities:  

Mesh:

Year:  2009        PMID: 20608345

Source DB:  PubMed          Journal:  J R Coll Physicians Edinb        ISSN: 1478-2715


  13 in total

1.  Hepatic alterations during the development and progression of cancer cachexia.

Authors:  Megan E Rosa-Caldwell; Jacob L Brown; David E Lee; Michael P Wiggs; Richard A Perry; Wesley S Haynie; Aaron R Caldwell; Tyrone A Washington; Wen-Juo Lo; Nicholas P Greene
Journal:  Appl Physiol Nutr Metab       Date:  2019-10-16       Impact factor: 2.665

Review 2.  Assessment of Cancer-Associated Cachexia - How to Approach Physical Function Evaluation.

Authors:  Julia Fram; Caroline Vail; Ishan Roy
Journal:  Curr Oncol Rep       Date:  2022-03-19       Impact factor: 5.075

3.  Insulin secretion decline in Walker-256 tumor-bearing rats is early, follows the course of cachexia, and is not improved by lixisenatide.

Authors:  Débora Luiza Quintilhano; Daniele Romani Miksza; Winny Beatriz de Souza Galia; Mahira Oliveira Ramalho Costa Ramalho; Camila Ferraz Lucena; Maíra Mello Rezende Valle; Maria Fernanda Rodrigues Graciano; Helenir Medri de Souza; Gisele Lopes Bertolini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-31       Impact factor: 3.000

4.  The cancer anorexia-cachexia syndrome: myth or reality?

Authors:  Wael Lasheen; Declan Walsh
Journal:  Support Care Cancer       Date:  2010-02       Impact factor: 3.603

5.  Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia.

Authors:  Hirak Der-Torossian; Ashley Wysong; Scott Shadfar; Monte S Willis; Jonathan McDunn; Marion E Couch
Journal:  J Cachexia Sarcopenia Muscle       Date:  2013-01-24       Impact factor: 12.910

6.  Differences in routine laboratory parameters related to cachexia between patients with hematological diseases and patients with solid tumors or heart failure - is there only one cachexia?

Authors:  Tomislav Letilovic; Sonja Perkov; Zlata Flegar Mestric; Radovan Vrhovac
Journal:  Nutr J       Date:  2013-01-07       Impact factor: 3.271

7.  Emerging markers of cachexia predict survival in cancer patients.

Authors:  Patrizia Mondello; Antonio Lacquaniti; Stefania Mondello; Davide Bolignano; Vincenzo Pitini; Carmela Aloisi; Michele Buemi
Journal:  BMC Cancer       Date:  2014-11-16       Impact factor: 4.430

8.  Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trial.

Authors:  Valiollah Mehrzad; Rohollah Afshar; Mojtaba Akbari
Journal:  Adv Biomed Res       Date:  2016-03-22

9.  Are Four Simple Questions Able to Predict Weight Loss in Outpatients With Metastatic Cancer? A Prospective Cohort Study Assessing the Simplified Nutritional Appetite Questionnaire.

Authors:  Seth F Helfenstein; Alexandra Uster; Maya Rühlin; Miklos Pless; Peter E Ballmer; Reinhard Imoberdorf
Journal:  Nutr Cancer       Date:  2016-07-01       Impact factor: 2.900

10.  Gut disruption impairs rehabilitation in patients curatively operated for pancreaticoduodenal cancer - a qualitative study.

Authors:  Kristine Elberg Dengsø; Tine Tjørnhøj-Thomsen; Susanne Oksbjerg Dalton; Bo Marcel Christensen; Jens Hillingsø; Thordis Thomsen
Journal:  BMC Cancer       Date:  2018-10-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.